Zenas's obexelimab filings advance on both sides of the Atlantic; US verdict due May 2027
US regulators have accepted Zenas's biologics filing and European reviewers have started assessing its parallel application, as the company reports $647.1m in cash and investments.
Zenas BioPharma now has a dated regulatory test for obexelimab. On 5 November 2026 the company said the US Food and Drug Administration had accepted its biologics licence application for IgG4-related disease and set a decision goal of 27 May 2027, just under seven months away. The European Medicines Agency has also validated the company's marketing authorisation application for the same use.
The company said both filings draw on results from its Phase 3 INDIGO trial, together with bioequivalence data comparing a prefilled pen with a syringe. The device data suggest Zenas wants both ways of delivering the drug covered in the submissions, though the company's statement as reported does not spell out its launch plans.
Validation in Europe is an administrative step: it means the dossier is complete enough for formal scientific assessment to begin, and it says nothing about the likely outcome. No European decision timetable was given in the information available.
The announcement came with third-quarter 2026 results, which showed $647.1m in cash and investments. Zenas also said topline data from SunStone, a Phase 2 study in systemic lupus erythematosus, are expected in the fourth quarter. Details on pricing, expected competition and commercial forecasts were not part of the disclosure.
Why it matters
- A fixed US decision date of 27 May 2027 gives investors, partners and rivals a concrete point against which to measure Zenas's first potential product.
- Running US and EU reviews in parallel puts obexelimab under two regulators at once, though European approval and timing remain uncertain.
- Including pen-versus-syringe bioequivalence data suggests presentation is part of the regulatory case, which matters to device and quality teams.
- The fourth-quarter SunStone readout in lupus will show whether obexelimab has a wider development path beyond IgG4-related disease.
Company's press release (SEC filing): Zenas BioPharma, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
Imricor starts US launch of NorthStar iMR system after paediatric FDA clearances
FDA grants NeOnc Type B meeting on accelerated approval path for intranasal NEO100
CHMP backs Cosentyx for adolescents aged 12+ with moderate-to-severe hidradenitis suppurativa
TuHURA wins FDA IND clearance for VISTA antibody TBS-2025 in relapsed AML
CHMP backs Roche's Gazyvaro as add-on therapy for autoantibody-positive lupus
